Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 6/20 | 0.37 |
| ▸ | NQO1 | P15559 | 1/20 | 0.36 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.36 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 2/20 | 0.31 |
| ▸ | PANK3 | Q9H999 | 2/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13515892 | 0.80 | NQO1 (0.36) | NQO1CAMKK2SOS2CTSBPANK3 | |
| SCHEMBL22135837 | 0.78 | CAMKK2 (0.35) | EGLN2NQO1CAMKK2SOS2LMNA | |
| SCHEMBL27798702 | 0.77 | NQO1 (0.33) | EGLN2NQO1 | |
| SCHEMBL19117561 | 0.76 | NQO1 (0.44) | NQO1CAMKK2IDH1 | |
| SCHEMBL19249160 | 0.76 | KDM5A (0.34) | NQO1CAMKK2SOS2PANK3KDM5A | |
| SCHEMBL701812 | 0.74 | NOS3 (0.44) | EGLN2NQO1SOS2HTR2B | |
| SCHEMBL24679262 | 0.73 | CAMKK2 (0.45) | NQO1CAMKK2SOS2CTSBPANK3 | |
| SCHEMBL18134405 | 0.73 | ADORA1 (0.41) | CAMKK2KDM5A | |
| SCHEMBL26081486 | 0.73 | CAMKK2 (0.33) | NQO1CAMKK2SOS2PANK3 | |
| SCHEMBL21928096 | 0.72 | EGLN2 (0.40) | EGLN2NQO1SOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827662-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230250129-A1 | NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | SAGE THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230250129-A1 | NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | SAGE THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-11325930-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| WO-2021262836-A1 | 3.ALPHA.-HYDROXY, 17.BETA.-C(O)-N-ARYL SUBSTITUTED NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | SAGE THERAPEUTICS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| US-20210147454-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2021-05-20 | — | — | US | disclosed |
| US-20200392170-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2020-12-17 | — | — | US | disclosed |
| WO-2020132504-A1 | 3.ALPHA.-HYDROXY-17.BETA.-AMIDE NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | SAGE THERAPEUTICS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-9878995-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170233405-A1 | MAX BINDERS AS MYC MODULATORS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2017-08-17 | — | — | US | disclosed |
| US-20170152240-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170008905-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
| WO-2017007689-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2017-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325930-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | EGLN2 848/4885NQO1 603/4885CAMKK2 434/4885 |
| US-20200392170-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | EGLN2 848/4885NQO1 603/4885CAMKK2 434/4885 |
| US-20230250129-A1 | NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | MC2R, NR3C2, AVPR1B | EGLN2 3641/4885NQO1 3004/4885CAMKK2 2416/4885 |
| US-20170152240-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | EGLN2 848/4885NQO1 603/4885CAMKK2 434/4885 |
| US-20170233405-A1 | MAX BINDERS AS MYC MODULATORS AND USES THEREOF | MYC, MYCBP, MYCBP2 | EGLN2 4308/4885NQO1 2395/4885CAMKK2 1912/4885 |
| US-20170008905-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | EGLN2 848/4885NQO1 603/4885CAMKK2 434/4885 |
| US-20210147454-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | EGLN2 848/4885NQO1 603/4885CAMKK2 434/4885 |
| US-11827662-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | EGLN2 848/4885NQO1 603/4885CAMKK2 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.